DelveInsight’s “Deep Vein Thrombosis Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Deep Vein Thrombosis, historical and forecasted epidemiology as well as the Deep Vein Thrombosis market trends in the United States, EU4 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
To Know in detail about the Deep Vein Thrombosis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Deep Vein Thrombosis Market Forecast
Some of the key facts of the Deep Vein Thrombosis Market Report:
- The Deep Vein Thrombosis market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
- Waheed et al. (2021) estimate that there are 80 instances of DVT annually per 100,000 people, with a prevalence of lower limb DVT of 1 case per 1000 people
- The exact number of persons who suffer from deep vein thrombosis (DVT) or pulmonary embolism (PE) is unknown, however the CDC (2022) estimates that as many as 900,000 people could be impacted each year in the United States
- Approximately 33% of persons with DVT/PE will experience a recurrence within 10 years, according to CDC data (2022)
- Growing healthcare awareness and rising income levels in emerging economies could hasten the expansion of the deep vein thrombosis market. People's increased awareness of cutting-edge DVT therapies is mostly due to digitalization, which has fueled the industry
- Key Deep Vein Thrombosis Companies: Anthos Therapeutics, Inc., Mercator MedSystems, Inc., Bayer, Pfizer, Biocad, MinaPharm Pharmaceuticals, LEO Pharma, Agen Biomedical, Bristol-Myers Squibb, Daiichi Sankyo, Inc., Sanofi, and others
- Key Deep Vein Thrombosis Therapies: Abelacimab, Perivascular dexamethasone, Rivaroxaban (Xarelto, BAY59-7939), Apixaban, Sodium Enoxaparine, r-Hirudin, innohep®, ThromboView, Apixaban, Warfarin, edoxaban tosylate, Idrabiotaparinux sodium, SanOrg34006, Tinzaparin, and others
- The Deep Vein Thrombosis market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Deep Vein Thrombosis pipeline products will significantly revolutionize the Deep Vein Thrombosis market dynamics.
Deep Vein Thrombosis Overview
A blood clot known as deep vein thrombosis (DVT) develops in the deep veins, commonly in the legs, but it can also happen in the arms, mesenteric, and cerebral veins. It is a symptom of venous thromboembolism disorders, which rank third among cardiovascular diseases in terms of fatalities after heart attacks and strokes.
Get a Free sample for the Deep Vein Thrombosis Market Report
https://www.delveinsight.com/report-store/deep-vein-thrombosis-market
Deep Vein Thrombosis Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Deep Vein Thrombosis Epidemiology Segmentation:
The Deep Vein Thrombosis market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:
- Total Prevalence of Deep Vein Thrombosis
- Prevalent Cases of Deep Vein Thrombosis by severity
- Gender-specific Prevalence of Deep Vein Thrombosis
- Diagnosed Cases of Episodic and Chronic Deep Vein Thrombosis
Download the report to understand which factors are driving Deep Vein Thrombosis epidemiology trends @ Deep Vein Thrombosis Epidemiology Forecast
Deep Vein Thrombosis Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Deep Vein Thrombosis market or expected to get launched during the study period. The analysis covers Deep Vein Thrombosis market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Deep Vein Thrombosis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Deep Vein Thrombosis Therapies and Key Companies
- Abelacimab: Anthos Therapeutics, Inc.
- Perivascular dexamethasone: Mercator MedSystems, Inc.
- Rivaroxaban (Xarelto, BAY59-7939): Bayer
- Apixaban: Pfizer
- Sodium Enoxaparine: Biocad
- r-Hirudin, innohep®: MinaPharm Pharmaceuticals
- ThromboView: LEO Pharma
- Apixaban: Agen Biomedical
- Warfarin: Bristol-Myers Squibb
- edoxaban tosylate: Pfizer
- Idrabiotaparinux sodium: Daiichi Sankyo, Inc.
- SanOrg34006: Sanofi
- Tinzaparin: LEO Pharma
Discover more about therapies set to grab major Deep Vein Thrombosis market share @ Deep Vein Thrombosis Treatment Market
Deep Vein Thrombosis Market Strengths
- The use of off-label branded and generic prescription medications targeted at individual symptoms of DVT
- Several academic institutions and pharmaceutical companies are currently conducting clinical trials for the treatment of various symptoms of Deep Vein Thrombosis (DVT)
Deep Vein Thrombosis Market Opportunities
- New therapeutic options are needed to address the unmet need for effective and curative therapies for Deep Vein Thrombosis (DVT). This has created an opportunity for key players to develop novel therapies targeted towards this indication
Scope of the Deep Vein Thrombosis Market Report
- Study Period: 2019–2032
- Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
- Key Deep Vein Thrombosis Companies: Anthos Therapeutics, Inc., Mercator MedSystems, Inc., Bayer, Pfizer, Biocad, MinaPharm Pharmaceuticals, LEO Pharma, Agen Biomedical, Bristol-Myers Squibb, Daiichi Sankyo, Inc., Sanofi, and others
- Key Deep Vein Thrombosis Therapies: Abelacimab, Perivascular dexamethasone, Rivaroxaban (Xarelto, BAY59-7939), Apixaban, Sodium Enoxaparine, r-Hirudin, innohep®, ThromboView, Apixaban, Warfarin, edoxaban tosylate, Idrabiotaparinux sodium, SanOrg34006, Tinzaparin, and others
- Deep Vein Thrombosis Therapeutic Assessment: Deep Vein Thrombosis current marketed and Deep Vein Thrombosis emerging therapies
- Deep Vein Thrombosis Market Dynamics: Deep Vein Thrombosis market drivers and Deep Vein Thrombosis market barriers
- Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
- Deep Vein Thrombosis Unmet Needs, KOL’s views, Analyst’s views, Deep Vein Thrombosis Market Access and Reimbursement
To know more about Deep Vein Thrombosis companies working in the treatment market, visit @ Deep Vein Thrombosis Clinical Trials and Therapeutic Assessment
Table of Contents
1. Deep Vein Thrombosis Market Report Introduction
2. Executive Summary for Deep Vein Thrombosis
3. SWOT analysis of Deep Vein Thrombosis
4. Deep Vein Thrombosis Patient Share (%) Overview at a Glance
5. Deep Vein Thrombosis Market Overview at a Glance
6. Deep Vein Thrombosis Disease Background and Overview
7. Deep Vein Thrombosis Epidemiology and Patient Population
8. Country-Specific Patient Population of Deep Vein Thrombosis
9. Deep Vein Thrombosis Current Treatment and Medical Practices
10. Deep Vein Thrombosis Unmet Needs
11. Deep Vein Thrombosis Emerging Therapies
12. Deep Vein Thrombosis Market Outlook
13. Country-Wise Deep Vein Thrombosis Market Analysis (2019–2032)
14. Deep Vein Thrombosis Market Access and Reimbursement of Therapies
15. Deep Vein Thrombosis Market Drivers
16. Deep Vein Thrombosis Market Barriers
17. Deep Vein Thrombosis Appendix
18. Deep Vein Thrombosis Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email:Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services
